Palavras-chave
Como Citar
Resumo
Given the amount of scientific knowledge produced and published daily about the new corovavirus, this study sought to review evidence on some of the drugs used to treat Acute Respiratory Infection Syndrome caused by the COVID-19 virus. Thus, antimalarials and antiparasitics were evaluated regarding chemical and pharmacological aspects, including mechanism of action, toxicity, adverse effects and recommendation for use in the treatment of COVID-19.
Referências
ADER, F. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open, [s. l.], v. 10, n. 9, p. e041437, 2020. Available at: https://doi.org/10.1136/bmjopen-2020-041437
ANVISA. Bulário Eletrônico. [S. l.], 2007. Available at: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.
ANVISA. Nota de esclarecimento sobre a ivermectina. [s. l.], 2020. Available at: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2020/nota-de-esclarecimento-sobre-a-ivermectina
BANERJEE, K. et al. The Battle against COVID 19 Pandemic: What we Need to Know Before we “Test Fire” Ivermectin. Drug Research, [s. l.], v. 70, n. 08, p. 337–340, 2020. Available at: https://doi.org/10.1055/a-1185-8913
CELİK, I.; ONAY-BESİKCİ, A.; AYHAN-KILCIGİL, G. Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. Journal of Biomolecular Structure and Dynamics, [s. l.], p. 1–7, 2020. Available at: https://doi.org/10.1080/07391102.2020.1792993
COLSON, P. et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. International Journal of Antimicrobial Agents, [s. l.], v. 55, n. 4, p. 105932, 2020. Available at: https://doi.org/10.1016/j.ijantimicag.2020.105932
DELVECCHIO, R. et al. Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. Viruses, [s. l.], v. 8, n. 12, p. 322, 2016. Available at: https://doi.org/10.3390/v8120322
GAMIÑO-ARROYO, A. E. et al. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Clinical Infectious Diseases, [s. l.], v. 69, n. 11, p. 1903–1911, 2019. Available at: https://doi.org/10.1093/cid/ciz100
GUPTA, A.; MALVIYA, A. Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter. Postgraduate Medical Journal, [s. l.], p. postgradmedj-2020-138585, 2020. Available at: https://doi.org/10.1136/postgradmedj-2020-138585
HEMMATI, F. et al. Mysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV. Archives of Medical Research, [s. l.], v. 51, n. 5, p. 375–383, 2020. Available at: https://doi.org/10.1016/j.arcmed.2020.04.022
LACAVA, A. C. Complicações oculares da terapêutica com a cloroquina e derivados. Arquivos Brasileiros de Oftalmologia, [s. l.], v. 73, n. 4, p. 384–389, 2010. Available at: https://doi.org/10.1590/S0004-27492010000400019
MAHMOUD, D. B.; SHITU, Z.; MOSTAFA, A. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? Journal of Genetic Engineering and Biotechnology, [s. l.], v. 18, n. 1, p. 35, 2020. Available at: https://doi.org/10.1186/s43141-020-00055-5
MENEZES, C. R.; SANCHES, C.; CHEQUER, F. M. D. Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento? Journal of Health & Biological Sciences, [s. l.], v. 8, n. 1, p. 1, 2020. Available at: https://doi.org/10.12662/2317-3076jhbs.v8i1.3206.p1-9.2020
MINISTÉRIO DA SAÚDE. Diretrizes para diagnostico e tratamento da COVID-19 versão 1. [S. l.], 2020a.
MINISTÉRIO DA SAÚDE. Guia de vigilância epidemiológica Covid-19. [s. l.], 2020b.
NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. PubChem Compound Summary for CID 41684, Nitazoxanide. [s. l.], 2005. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/41684
NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. PubChem Compound Summary for CID 6321424, Ivermectin. [s. l.], [s. d.]. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Ivermectin
PAHO. Folha informativa COVID-19 - Escritório da OPAS e da OMS no Brasil - OPAS/OMS. [S. l.], 2020a. Available at: https://www.paho.org/pt/covid19#cloroquina.
PAHO. Ongoing Living Update of Potential COVID-19 Therapeutics : summary of rapid systematic reviews. [S. l.], 2020b.
PAHO. Recomendação sobre o uso de ivermectina no tratamento de COVID-19. [s. l.], 2020c. Available at: https://iris.paho.org/bitstream/handle/10665.2/52462/OPASIMSCDECOVID-19200033_por.pdf?sequence=1&isAllowed=y
PONCHET, M. R. N. C. et al. Avaliação dos efeitos adversos desencadeados pelo uso de difosfato de cloroquina, com ênfase na retinotoxicidade, em 350 doentes com lúpus eritematoso. Anais Brasileiros de Dermatologia, [s. l.], v. 80, n. suppl 3, p. S275–S282, 2005. Available at: https://doi.org/10.1590/s0365-05962005001000003
RIZZO, E. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg’s Archives of Pharmacology, [s. l.], v. 393, n. 7, p. 1153–1156, 2020. Available at: https://doi.org/10.1007/s00210-020-01902-5
ROSA, S. G. V.; SANTOS, W. C. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública, [s. l.], v. 44, p. 1, 2020. Available at: https://doi.org/10.26633/RPSP.2020.40
ROSSIGNOL, J.-F. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. Journal of Infection and Public Health, [s. l.], v. 9, n. 3, p. 227–230, 2016. Available at: https://doi.org/10.1016/j.jiph.2016.04.001
ROSSIGNOL, J.-F. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Research, [s. l.], v. 110, p. 94–103, 2014. Available at: https://doi.org/10.1016/j.antiviral.2014.07.014
SIDDIQI, H. K.; MEHRA, M. R. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. The Journal of Heart and Lung Transplantation, [s. l.], v. 39, n. 5, p. 405–407, 2020. Available at: https://doi.org/10.1016/j.healun.2020.03.012
SUÁREZ-MUTIS, M. C.; MARTÍNEZ-ESPINOSA, F. E.; CLAUDIA GARCIA SERPA OSORIO-DE-CASTRO. Orientações sobre a Cloroquina_Nota tecnica .pdf. Instituto Oswaldo Cruz, [s. l.], v. 1, n. 1, p. 1–7, 2020.
WAGSTAFF, K. M. et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal, [s. l.], v. 443, n. 3, p. 851–856, 2012. Available at: https://doi.org/10.1042/BJ20120150
WORLD HEALTH ORGANIZATION. Coronavirus disease (COVID-19). [S. l.], 2020. Available at: ttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19.
WORLD HEALTH ORGANIZATION. Solidarity clinical trial for COVID-19 treatments. [S. l.], [s. d.]. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-COVID-19-treatments.
ZHOU, D.; DAI, S.-M.; TONG, Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Journal of Antimicrobial Chemotherapy, [s. l.], v. 75, n. 7, p. 1667–1670, 2020. Available at: https://doi.org/10.1093/jac/dkaa114